Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Two biosimilars get U.S. panel’s nod
by Michael McCoy
July 18, 2016
| A version of this story appeared in
Volume 94, Issue 29
An FDA advisory panel voted unanimously last week to recommend that the agency approve biosimilar versions of two multi-billion-dollar-selling arthritis drugs. FDA often accepts such panels’ recommendations. The panel voted 20-0 in support of Sandoz’s version of Enbrel, an Amgen drug that is used to treat arthritis and psoriasis. The panel also voted 26-0 in favor of approving Amgen’s version of the AbbVie arthritis drug Humira. In the latter case, AbbVie claims to have patents that protect Humira from competition until at least 2022.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X